IZOTROPIC CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.12 CAD | -14.29% |
|
-4.00% | +20.00% |
| Apr. 02 | Izotropic Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024 | CI |
| Jan. 30 | Izotropic Corporation Receives Response from U.S. FDA | CI |
Valuation
| Fiscal Period: April | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Capitalization 1 | 9.044 | 7.791 | 51.25 | 30.94 | 17.89 |
| Enterprise Value (EV) 1 | 8.736 | 7.177 | 47.18 | 31.11 | 19.86 |
| P/E ratio | -22.2 x | -5.64 x | -8.66 x | -4.47 x | -3.05 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | -28.1 x | -6.68 x | -9.78 x | -4.88 x | -3.81 x |
| EV / FCF | -36 x | -14.2 x | -42.1 x | -14.5 x | -15.2 x |
| FCF Yield | -2.78% | -7.04% | -2.37% | -6.91% | -6.58% |
| Price to Book | 28.5 x | 11 x | 11.3 x | -82.6 x | -5.82 x |
| Nbr of stocks (in thousands) | 23,190 | 29,965 | 42,006 | 44,841 | 51,855 |
| Reference price 2 | 0.3900 | 0.2600 | 1.220 | 0.6900 | 0.3450 |
| Announcement Date | 8/2/19 | 8/20/20 | 8/27/21 | 8/26/22 | 8/30/23 |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: April | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -0.5944 | -0.311 | -1.074 | -4.823 | -6.37 | -5.213 |
| EBIT 1 | -0.5989 | -0.3176 | -1.077 | -4.824 | -6.377 | -5.229 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -0.7301 | -0.3985 | -1.156 | -4.976 | -6.655 | -5.661 |
| Net income 1 | -0.7301 | -0.3985 | -1.156 | -4.976 | -6.655 | -5.661 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -0.0533 | -0.0176 | -0.0461 | -0.1409 | -0.1544 | -0.1130 |
| Free Cash Flow 1 | -0.3069 | -0.2425 | -0.505 | -1.121 | -2.151 | -1.306 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 8/28/18 | 8/2/19 | 8/20/20 | 8/27/21 | 8/26/22 | 8/30/23 |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: April | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 0.17 | 1.97 |
| Net Cash position 1 | 0.47 | 0.31 | 0.61 | 4.06 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -0.0269 x | -0.3785 x |
| Free Cash Flow 1 | -0.31 | -0.24 | -0.5 | -1.12 | -2.15 | -1.31 |
| ROE (net income / shareholders' equity) | -426% | -110% | -226% | -190% | -321% | 328% |
| ROA (Net income/ Total Assets) | -117% | -47.8% | -121% | -110% | -115% | -241% |
| Assets 1 | 0.6255 | 0.834 | 0.958 | 4.509 | 5.807 | 2.348 |
| Book Value Per Share 2 | 0.0200 | 0.0100 | 0.0200 | 0.1100 | -0.0100 | -0.0600 |
| Cash Flow per Share 2 | 0.0200 | 0.0100 | 0.0200 | 0.1000 | 0.0400 | 0 |
| Capex 1 | 0.02 | - | - | - | 0.02 | 0.04 |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 8/28/18 | 8/2/19 | 8/20/20 | 8/27/21 | 8/26/22 | 8/30/23 |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +20.00% | 5.62M | |
| -3.22% | 14.6B | |
| -36.36% | 2.71B | |
| -12.35% | 2.44B | |
| -12.00% | 1.51B | |
| -.--% | 1.12B | |
| +40.97% | 518M | |
| +89.74% | 502M | |
| +12.77% | 239M | |
| +1.30% | 183M |
- Stock Market
- Equities
- IZO Stock
- Financials Izotropic Corporation
